PYC

Pyc Therapeutics

Pharmaceuticals, Biotechnology & Life Sciences

PYC Therapeutics is a clinical-stage biotech company focused on developing RNA therapies to address genetic diseases. Their proprietary RNA delivery platform aims to provide safer and more effective treatments by targeting the underlying causes of these diseases. The company is advancing a pipeline of novel therapies for eye, central nervous system, and kidney diseases.

Biotechnology

RNA Therapies

Genetic Diseases

Drug Discovery

Shorted

short percentage0.42%

reported shorts2.4M

shares on issue583.260M

About

website

pyctx.com

industry

Pharmaceuticals, Biotechnology & Life Sciences

address

Suite 8, 7 The Esplanade, MT PLEASANT, WA, AUSTRALIA, 6153

Connect

Key Metrics

market cap

$1.39B

eps$-0.10

More Pharmaceuticals, Biotechnology & Life Sciences Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

Biotechnology

RNA Therapies

Genetic Diseases

Drug Discovery

Clinical Stage

Company Overview

AI-generated company summary

Company History

PYC Therapeutics was founded with the mission to revolutionize the treatment of genetic diseases through RNA therapies. Over the years, the company has evolved into a leader in RNA therapeutic development, focusing on monogenic diseases. They have achieved significant milestones in advancing their clinical and pre-clinical programs, particularly in the areas of ophthalmology and neurology.

Competitive Advantages

PYC Therapeutics' competitive advantages include a proprietary RNA delivery platform that enhances the safety and efficacy of treatments, a focus on monogenic diseases which have a higher probability of successful drug development, and a strategic pipeline targeting high-need areas such as eye and central nervous system diseases.

Risk Factors

•Regulatory approval challenges
•High R&D costs
•Competition from other biotech firms

Recent Developments

Last 6 months

In the past six months, PYC Therapeutics has continued to advance its clinical programs and presented new findings at major global conferences, highlighting their progress in RNA therapeutics for genetic diseases.

Key People

Leadership team at Pyc Therapeutics

Unavailable

CEO

Unavailable

CFO